Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/b, Open-Label, Dose-Escalation and Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor, as a Single Agent and in Combination With Nivolumab, a PD-1 Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

NCT04200963 is registered in ClinicalTrials.gov with Ikena Oncology as lead sponsor.

NCT NCT04200963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04200963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/b, Open-Label, Dose-Escalation and Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor, as a Single Agent and in Combination With Nivolumab, a PD-1 Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Lead sponsor
Ikena Oncology
Phase
Phase 1
Overall status
Completed
Start date
December 18, 2019
Completion date
July 18, 2023
Enrollment
78 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumor, bladder cancer, bladder disease, bladder neoplasm, bladder urothelial carcinoma, locally advanced solid tumor, metastatic bladder cancer, metastatic cancer, metastatic urothelial carcinoma, neoplasm malignant, neoplasm metastasis, neoplasm, bladder, neoplasm, urinary bladder, neoplasms, solid carcinoma, solid tumor, solid tumor, adult, urothelial carcinoma, urothelial carcinoma bladder, urothelial neoplasm